| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/19/2005 | EP1498118A1 Patch and process for producing the same |
| 01/19/2005 | EP1498116A1 Method of manufacturing chemical-containing composite particles |
| 01/19/2005 | EP1498115A1 Preparation of particles for inhalation |
| 01/19/2005 | EP1498104A1 Hair growth tonic |
| 01/19/2005 | EP1498101A1 Composition for cell proliferation |
| 01/19/2005 | EP1497672A2 Ultrasonic doppler effect speed measurement |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497467A2 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 01/19/2005 | EP1497462A2 Genomic screen for epigenetically silenced genes associated with cancer |
| 01/19/2005 | EP1497442A2 Biologic modulations with nanoparticles |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497424A1 Oligonucleotide compositions and their use for the modulation of immune responses |
| 01/19/2005 | EP1497420A2 Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| 01/19/2005 | EP1497309A2 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity |
| 01/19/2005 | EP1497308A1 Method for producing steroid crystals, crystals obtained by said method and their use in pharmaceutical formulations |
| 01/19/2005 | EP1497298A1 Derivatives of 2,2,4-trisubstituted tetrahydrofuran as antifungal agents |
| 01/19/2005 | EP1497297A1 Polymorph of ascomycin derivative |
| 01/19/2005 | EP1497296A1 1,4 DIAZOCINO 7,8,1-hi INDOLE DERIVATIVES AS ANTIPSYCHOTIC AND ANTIOBESITY AGENTS |
| 01/19/2005 | EP1497295A1 Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
| 01/19/2005 | EP1497294A1 1,2,3,4,7,8-HEXAHYDRO-6 i H /i - 1,4 DIAZEPINO 6,7 ,1- i 1J /i QUINOLINE DERIVATIVES AS ANTIPSYCHOTIC AND ANTI OBESITY AGENTS |
| 01/19/2005 | EP1497293A1 (1,4)diazepino(6,7,1-ij)quinoline derivatives as anti psychotic and antiobesity agents |
| 01/19/2005 | EP1497292A1 Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents |
| 01/19/2005 | EP1497291A2 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| 01/19/2005 | EP1497290A1 Process for preparing acid salts of gemifloxacin |
| 01/19/2005 | EP1497289A1 Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 01/19/2005 | EP1497288A1 Novel ester hydroxy-substituted nitrogen heterocycles as antagonists of the muscarinic m3 receptor, methods for the production thereof, and use thereof as a medicament |
| 01/19/2005 | EP1497287A1 Quinolinone derivatives |
| 01/19/2005 | EP1497286A1 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents |
| 01/19/2005 | EP1497285A1 Benzoxazinone-derived compounds, their preparation und use as medicaments |
| 01/19/2005 | EP1497280A1 Indol-2-ones as selective inhibitors of cyclooxygenase-2 |
| 01/19/2005 | EP1497279A2 Substituted indoles and their use as 5ht-reuptake inhibitors and as 5ht ligands |
| 01/19/2005 | EP1497278A1 Heterocyclic amide derivatives as cytokine inhibitors |
| 01/19/2005 | EP1497274A2 Terphenyl derivatives, preparation thereof, compositions containing same |
| 01/19/2005 | EP1497273A2 Hydroxamic acid derivatives |
| 01/19/2005 | EP1497272A2 Method of preparing amine stereoisomers |
| 01/19/2005 | EP1497271A1 Indane acetic acid derivatives and their use as pharmaceutical agents |
| 01/19/2005 | EP1497268A2 Nitric oxide donors, compositions and methods of use |
| 01/19/2005 | EP1497266A2 Quinoline derivatives and their use as 5-ht6 ligands |
| 01/19/2005 | EP1497265A1 Compounds having affinity at 5ht2c receptor and use thereof in therapy |
| 01/19/2005 | EP1497262A1 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof |
| 01/19/2005 | EP1497261A1 Phenethanolamine derivatives |
| 01/19/2005 | EP1497258A1 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
| 01/19/2005 | EP1497257A1 2,5-bis-diamine-[1,4] benzoquinone derivatives for the treatment of alzheimer's disease, a process for their preparation and intermediates therefor |
| 01/19/2005 | EP1497256A1 Substituted 1,5-diaminopentan-3-ol compounds |
| 01/19/2005 | EP1497250A1 Hyperforin derivatives, the use thereof and formulations containing them |
| 01/19/2005 | EP1497249A1 Hyperforin halogenated derivatives, the use thereof and formulations containing them |
| 01/19/2005 | EP1497247A2 Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| 01/19/2005 | EP1497019A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/19/2005 | EP1496995A1 Method and apparatus for ultrasound treatment of connective tissue |
| 01/19/2005 | EP1496981A2 Method of treating cancer |
| 01/19/2005 | EP1496967A1 Therapeutic dry powder preparation |
| 01/19/2005 | EP1496947A1 Removal of adenine during a process of pathogen reducing blood and blood components |
| 01/19/2005 | EP1496941A1 Glycodendrimers having biological activity |
| 01/19/2005 | EP1496940A2 Methods of treating diabetes using pde 11a inhibitors |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496933A2 Use of interleukin-19 to treat ovarian cancer |
| 01/19/2005 | EP1496925A2 Use of interleukin-24 to treat ovarian cancer |
| 01/19/2005 | EP1496923A1 Cancer immunotherapy |
| 01/19/2005 | EP1496920A1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 01/19/2005 | EP1496918A1 Pharmaceutical composition comprising arsenite for the treatment of malignancy |
| 01/19/2005 | EP1496917A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 01/19/2005 | EP1496916A2 Metastasis modulating activity of highly sulfated oligosaccharides |
| 01/19/2005 | EP1496915A1 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| 01/19/2005 | EP1496914A1 (20S)-1a-HYDROXY-2a-METHYL AND 2&bgr;-METHYL-19-NOR-VITAM IN D sb 3 /sb AND THEIR USES |
| 01/19/2005 | EP1496913A2 Neuroprotective spirostenol pharmaceutical compositions |
| 01/19/2005 | EP1496912A1 Combination of brimonidine and timolol for topical ophthalmic use |
| 01/19/2005 | EP1496911A1 Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases |
| 01/19/2005 | EP1496910A1 Kinase inhibitors |
| 01/19/2005 | EP1496909A1 Combination therapy for the treatment of cancer |
| 01/19/2005 | EP1496908A1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer |
| 01/19/2005 | EP1496907A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496906A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496905A2 Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| 01/19/2005 | EP1496904A1 Pharmaceutical containing n, n'-disubstituted piperazine compounds |
| 01/19/2005 | EP1496903A1 Anhydrovinblastine for the treatment of cancer |
| 01/19/2005 | EP1496902A1 Medicaments containing steroids and a novel anticholinesterase drug |
| 01/19/2005 | EP1496901A2 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 01/19/2005 | EP1496900A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| 01/19/2005 | EP1496899A1 Use of materials having zinc ionophoric behavior |
| 01/19/2005 | EP1496898A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496897A1 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496896A1 Inhibitors of akt activity |
| 01/19/2005 | EP1496895A1 Use of cyclopamine in the treatment of psoriasis and other skin disorders |
| 01/19/2005 | EP1496894A1 Angiogenesis inhibitors |
| 01/19/2005 | EP1496893A2 Neuroprotectant methods, compositions, and screening methods thereof |
| 01/19/2005 | EP1496892A2 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 01/19/2005 | EP1496891A2 Methods for modulating phototoxicity |
| 01/19/2005 | EP1496890A1 Substituted beta-aminoalcohols used as medicaments |
| 01/19/2005 | EP1496889A1 Stabilized ascorbic acid derivatives |
| 01/19/2005 | EP1496888A1 Non-toxix amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents |
| 01/19/2005 | EP1496887A1 Personal care compositions comprising a zinc containing material in an aqueous surfactant composition |
| 01/19/2005 | EP1496886A1 Knockout mice and their use |
| 01/19/2005 | EP1496885A1 Use of conjugated linoleic acid derivatives |
| 01/19/2005 | EP1496884A1 Association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases |
| 01/19/2005 | EP1496883A1 Method for treating ileus with an alpha-ketoalkanoic acid, ester or amide |
| 01/19/2005 | EP1496882A1 Tolterodine salts |
| 01/19/2005 | EP1496881A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| 01/19/2005 | EP1496880A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTI-NEOPLASTIC AGENTS |